ANTX
Price:
$1.515
Market Cap:
$45.27M
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.[Read more]
Industry
Biotechnology
IPO Date
2022-03-25
Stock Exchange
NASDAQ
Ticker
ANTX
According to AN2 Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.76. This represents a change of -75.53% compared to the average of -3.11 of the last 4 quarters.
The mean historical PE Ratio of AN2 Therapeutics, Inc. over the last ten years is -19.56. The current -0.76 PE Ratio has changed 288.54% with respect to the historical average. Over the past ten years (40 quarters), ANTX's PE Ratio was at its highest in in the September 2024 quarter at -0.63. The PE Ratio was at its lowest in in the March 2021 quarter at -26.41.
Average
-19.56
Median
-13.44
Minimum
-51.21
Maximum
-4.46
Discovering the peaks and valleys of AN2 Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 67.54%
Maximum Annual PE Ratio = -4.46
Minimum Annual Increase = -66.82%
Minimum Annual PE Ratio = -51.21
Year | PE Ratio | Change |
---|---|---|
2023 | -7.47 | 67.54% |
2022 | -4.46 | -66.82% |
2021 | -13.44 | -36.67% |
2020 | -21.22 | -58.57% |
The current PE Ratio of AN2 Therapeutics, Inc. (ANTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-8.46
5-year avg
-19.56
10-year avg
-19.56
AN2 Therapeutics, Inc.’s PE Ratio is greater than Aerovate Therapeutics, Inc. (-0.89), greater than Adagene Inc. (-3.28), greater than Acrivon Therapeutics, Inc. Common Stock (-3.56), greater than Rezolute, Inc. (-5.42), greater than Anebulo Pharmaceuticals, Inc. (-4.71), greater than Mineralys Therapeutics, Inc. (-4.23), greater than Molecular Partners AG (-2.70), greater than Pharvaris N.V. (-7.75), greater than PepGen Inc. (-2.47), greater than PMV Pharmaceuticals, Inc. (-1.62), greater than Eliem Therapeutics, Inc. (-2.42), less than MediciNova, Inc. (-0.04),
Company | PE Ratio | Market cap |
---|---|---|
-0.89 | $75.65M | |
-3.28 | $105.36M | |
-3.56 | $224.18M | |
-5.42 | $312.31M | |
-4.71 | $37.34M | |
-4.23 | $647.99M | |
-2.70 | $217.27M | |
-7.75 | $1.09B | |
-2.47 | $215.29M | |
-1.62 | $83.83M | |
-2.42 | $342.68M | |
-0.04 | $112.54M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AN2 Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like AN2 Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is AN2 Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for AN2 Therapeutics, Inc. (ANTX)?
What is the highest PE Ratio for AN2 Therapeutics, Inc. (ANTX)?
What is the 3-year average PE Ratio for AN2 Therapeutics, Inc. (ANTX)?
What is the 5-year average PE Ratio for AN2 Therapeutics, Inc. (ANTX)?
How does the current PE Ratio for AN2 Therapeutics, Inc. (ANTX) compare to its historical average?